Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Nov. 9 — Advancing biomedical innovation and health technology issues are expected to stay in the forefront of health-care issues for a Senate health panel in the next Congress.
With Republicans retaining control of both chambers, Sen. Lamar Alexander (R-Tenn.) likely will keep his position as chairman of the Health, Education, Labor, and Pensions Committee when the next Congress convenes in January. Alexander is working with ranking member Patty Murray (D-Wash.) to lead the Senate effort to pass a counterpart to the 21st Century Cures bill (H.R. 6). Cures is a bipartisan effort to spur new medical treatments. Lawmakers in both the House and the Senate have said they want to work on the bill when the lame duck session convenes Nov. 14.
Senate Majority Leader Mitch McConnell (R-Ky.) confirmed his plans to make Cures a priority during the lame duck session at a Nov. 9 press conference. “The president’s interested in the precision medicine part of that, the vice president is interested in the cancer moonshot part of it, I’m interested in the regenerative medicine part of it,” he said. “I’d like to see us finish that important new measure this year.”
Alexander also has expressed support for a number of research-related projects, including White House initiatives to advance precision medicine and the cancer “moonshot” to try to double the rate of progress on oncology treatments and prevention therapies.
In a post-election statement, Alexander congratulated President-elect Donald J. Trump and called on him and Congress to “work together to address the voices of anger and despair, and of hope, that we heard yesterday.” “This includes reducing Washington’s role in our lives, making it easier to find a good job and less expensive health care, and making our system more fair. It’s time to put the election behind us,” he said Nov. 9.
Reforming and possibly repealing the Affordable Care Act is likely to be a top priority in both the House and the Senate, and an aide to Alexander said one of his priorities for next year will be “enacting structural reforms to provide Americans relief from the Obamacare emergency in Tennessee and other states and to ensure that more Americans can access private health insurance plans that fit their needs and their budgets.”
Alexander’s priorities related to biomedical research include:
Alexander also said he wants to tackle laboratory-developed tests, which are key to the precision medicine initiative as accurate, reliable diagnostic screening tools will determine whether a patient will respond to a specific drug. In a September hearing, he criticized the FDA’s 2014 proposal to oversee these tests as doubling up on regulation already being done by the Centers for Medicare & Medicaid Services. In the next session, Alexander will work “to ensure access to affordable, reliable lab-developed tests.”
The HELP chairman’s office also listed “improving the flow of health information so that doctors can spend more time with patients, and patients can have easier access to their health information” as a priority, “at the same time, working to help ensure patients can trust that their sensitive health information is kept private and is protected from cyber threat.”
Mental health and substance abuse disorders also will remain a priority for the committee, his office said, “including improving access to treatment for the one in five American adults who suffers from mental illness and those in Tennessee and other states suffering from substance use disorders like addiction to opioid painkillers.”
Although rising drug costs became a top issue in the campaign, particularly for Democrats, Bloomberg Intelligence senior analyst Brian Rye said Nov. 9 he expects drug pricing won’t be as high a priority in a Republican Congress and Trump administration.
Referring to Democratic presidential nominee Hillary Clinton, Rye told Bloomberg BNA, “both she and Bernie Sanders did a whole campaign to make drug pricing a priority” but it’s just not one for Republicans.
“I think it falls well below Obamacare on their list of health-care priorities,” Rye said. A Republican majority also means Sen. Bernie Sanders (I-Vt.) won’t be the chairman of the HELP committee; he had made it clear he wanted that position after dropping out of the presidential race.
“That’s an important part of this,” Rye said, adding Sanders could have held a number of hearings and investigations on drug pricing and likely could have delayed user fee negotiations. “The universe of biopharmaceutical companies is probably pleased with the environment they’re going to be dealing with for at least the next the couple years.”
Mary Woolley, president and chief executive officer of Research!America, told Bloomberg BNA research for health has consistently been a bipartisan issue. She cited recent funding increases for the National Institutes of Health and other federal health agencies and efforts to advance Cures legislation to accelerate the discovery, development and delivery of new therapies.
“Senator Roy Blunt (R-Mo.), Senator Dick Durbin (D-Ill.), Representative Nita Lowey (D-N.Y.) and Representative Tom Cole (R-Okla.) are among the congressional leaders who strongly believe that support for research is key to addressing the many health challenges afflicting Americans,” she said in a Nov. 9 statement, referring to appropriators who have led labor-health funding issues. “We look forward to working with the next Congress and the new Administration to ensure that federally-funded research and private sector medical innovation rise to the top of national priorities.”
The Trump campaign didn’t release many positions on medical research, but president-elect Trump has said he supports funding for Alzheimer’s research ( 10 LSLR, 9/16/16 ). In an October 2015 radio interview posted by the left-leaning group Media Matters with conservative host Michael Savage, Trump criticized the NIH, saying “I hear so much about the NIH, and it’s terrible.”
The American Association for Cancer Research issued a statement calling on Trump to support the cancer moonshot initiative--an effort from President Barack Obama’s administration led by Vice President Joe Biden. “Failure to capitalize upon the scientific discoveries of today is simply not an option,” AACR CEO Margaret Foti and Nancy Davidson, who is director of the University of Pittsburgh Cancer Institute and AACR‘s president, said in a joint statement. “Therefore, we call on Trump to rally all Americans around this cause of making cancer research a national priority so that we are able to continue to make the strides required to eradicate cancer worldwide.”
To contact the reporter on this story: Jeannie Baumann in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)